These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 1979819

  • 21. Effect of prazosin and propranolol on lipoproteins of hypertensive patients.
    Hurt E, Velasco M, Silva H, Camejo G.
    Biomed Biochim Acta; 1987; 46(1):111-8. PubMed ID: 3107546
    [Abstract] [Full Text] [Related]

  • 22. The emerging problem of plasma lipid changes during antihypertensive therapy.
    Johnson BF.
    J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S213-21. PubMed ID: 6177959
    [Abstract] [Full Text] [Related]

  • 23. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
    Pool JL.
    Am Heart J; 1991 Jan; 121(1 Pt 2):251-9; discussion 259-60. PubMed ID: 1824647
    [Abstract] [Full Text] [Related]

  • 24. Effectiveness of interventions to reduce coronary heart disease risk.
    Adedeji OO, Oyakhire GK, Saeed AK, Ghamdi AI.
    West Afr J Med; 2011 Jan; 30(3):197-201. PubMed ID: 22120486
    [Abstract] [Full Text] [Related]

  • 25. [The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension].
    Daae LN, Kierulf P, Brusletto B, Westheim A, Holme I, Syvertsen JO.
    Tidsskr Nor Laegeforen; 1991 Apr 10; 111(9):1102-5. PubMed ID: 1827216
    [Abstract] [Full Text] [Related]

  • 26. Alpha 1 blockers: antihypertensives whose positive metabolic profile with regard to hyperinsulinaemia and lipid metabolism cannot be ignored.
    Waite MA.
    J Intern Med Suppl; 1991 Apr 10; 735():113-7. PubMed ID: 1675053
    [Abstract] [Full Text] [Related]

  • 27. Beta-blockers, plasma lipids, and coronary heart disease.
    Cruickshank JM.
    Circulation; 1990 Sep 10; 82(3 Suppl):II60-5. PubMed ID: 1975524
    [Abstract] [Full Text] [Related]

  • 28. Combined lipid-lowering and antihypertensive treatment as part of a strategy of multiple risk factor intervention.
    Macdonald NJ, Farish E, Stark S, Barnes JF, Rolton H, Saba SN, Elliott HL, Reid JL.
    J Hum Hypertens; 1991 Oct 10; 5(5):449-54. PubMed ID: 1770473
    [Abstract] [Full Text] [Related]

  • 29. Therapeutic intervention for hypercholesterolemia.
    Gotto AM.
    Clin Cardiol; 1992 Nov 10; 15(11 Suppl 3):III18-21; discussion III22-4. PubMed ID: 1477993
    [Abstract] [Full Text] [Related]

  • 30. When do we treat hypercholesterolemia?
    Brown WV.
    Clin Cardiol; 1992 Nov 10; 15(11 Suppl 3):III10-4; discussion III 15-7. PubMed ID: 1477992
    [Abstract] [Full Text] [Related]

  • 31. The role of exercise in reducing coronary heart disease and associated risk factors.
    Leclerc KM.
    J Okla State Med Assoc; 1992 Jun 10; 85(6):283-90. PubMed ID: 1474418
    [Abstract] [Full Text] [Related]

  • 32. The effects of adrenergic blockade on lipoproteins using the rat as an experimental model.
    Balasubramaniam S, Simons LA, Hickie JB, Chang S.
    Artery; 1990 Jun 10; 17(2):60-70. PubMed ID: 1968740
    [Abstract] [Full Text] [Related]

  • 33. Lipid and lipoprotein abnormalities associated with coronary heart disease in patients with insulin-dependent diabetes mellitus.
    Laakso M, Pyörälä K, Sarlund H, Voutilainen E.
    Arteriosclerosis; 1986 Jun 10; 6(6):679-84. PubMed ID: 2877651
    [Abstract] [Full Text] [Related]

  • 34. Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.
    Foxall TL, Shwaery GT, Stucchi AF, Nicolosi RJ, Wong SS.
    Am J Pathol; 1992 Jun 10; 140(6):1357-63. PubMed ID: 1351367
    [Abstract] [Full Text] [Related]

  • 35. Effect of doxazosin on plasma lipids and atherogenesis: a preliminary report.
    Kowala MC, Nicolosi RJ.
    J Cardiovasc Pharmacol; 1989 Jun 10; 13 Suppl 2():S45-9; discussion S49. PubMed ID: 2471015
    [Abstract] [Full Text] [Related]

  • 36. Hypertension, coronary risk and alpha-blockade.
    J Hum Hypertens; 1990 Oct 10; 4 Suppl 3():1-65. PubMed ID: 1979818
    [No Abstract] [Full Text] [Related]

  • 37. Triglyceride, high density lipoprotein, and coronary heart disease.
    Consens Statement; 1990 Oct 10; 10(2):1-28. PubMed ID: 1286136
    [Abstract] [Full Text] [Related]

  • 38. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension.
    Levy D, Walmsley P, Levenstein M.
    Am Heart J; 1996 May 10; 131(5):966-73. PubMed ID: 8615318
    [Abstract] [Full Text] [Related]

  • 39. When do we treat hypercholesterolemia?
    Brown WV.
    Clin Cardiol; 1992 Nov 10; 15(11):III10-4; discussion III15-7. PubMed ID: 1458691
    [Abstract] [Full Text] [Related]

  • 40. Influence of doxazosin on lipid transport in rats and hamsters.
    Ontko JA, Woodside WF.
    J Cardiovasc Pharmacol; 1989 Nov 10; 13 Suppl 2():S31-6; discussions 36-7. PubMed ID: 2471013
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.